WHD References

Home - WHD References



  1. Khomiak A, Brunner M, Kordes M, et al. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers. 2020;12(11):3234. doi:https://doi.org/10.3390/cancers12113234
  2. Lawler M, Davies L, Oberst S, et al. European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission. The Lancet Oncology. Published online November 2022. doi:https://doi.org/10.1016/s1470-2045(22)00540-x
  3. Mancera-Arteu M, Giménez E, Balmaña M, et al. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma. Journal of Proteomics. 2019;195:76-87. doi:https://doi.org/10.1016/j.jprot.2019.01.006
  4. Virág D, Kremmer T, Lőrincz K, et al. Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma. Molecules. 2021;26(19):6003. doi:https://doi.org/10.3390/molecules26196003
  5. World Health Organization. Cancer. World Health Organization. Published February 3, 2022. https://www.who.int/news-room/fact-sheets/detail/cancer
  6. Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer. 2021;20(1). doi:https://doi.org/10.1186/s12943-021-01441-4
  7. Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Annals of Oncology. Published online April 2021. doi:https://doi.org/10.1016/j.annonc.2021.03.206
  8. Voutsadakis IA. The Landscape of PIK3CA Mutations in Colorectal Cancer. Clinical Colorectal Cancer. Published online February 2021. doi:https://doi.org/10.1016/j.clcc.2021.02.003
  9. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. International Journal of Cancer. 2021;149(4). doi:https://doi.org/10.1002/ijc.33588
  10. Duggan B, O’Rourke D, Anderson N, et al. Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific. Frontiers in Oncology. 2022;12:1009014. doi:https://doi.org/10.3389/fonc.2022.1009014